세계의 조직학 및 세포학 시장 규모, 점유율, 동향 분석 보고서 : 검사 유형별, 제품별, 용도별, 지역별, 부문 예측(2025-2030년)

Histology And Cytology Market Growth & Trends:

The global histology and cytology market size is anticipated to reach USD 49.48 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 15.31% from 2025 to 2030. The factors contributing to market growth include increasing demand for early detection of diseases, increased standardization of pathology laboratories, and implementation of immunohistochemistry and innovation in microscopy.

Organizations are focusing on collaborations for the standardization of cytopathology globally, positively impacting market growth. For instance, in November 2022, a novel IARC GICR collaboration center was established in Kenya to advance cancer registration in sub-Saharan Africa via training. The collaborating center focuses on regional training courses and the implementation & development of the CanReg5 software.

Moreover, companies are launching novel and automated instruments for cytology which can be further attributed to the histology and cytology industry growth. For instance, in January 2021, F. Hoffmann-La Roche Ltd launched uPath HER2 (4B5) image analysis and uPath HER2 Dual ISH image analysis-two automated digital pathology algorithms that offer rapid & accurate patient diagnoses in breast cancer.

COVID-19 became a catalyst for changing traditional pathology workflows with the integration of artificial intelligence (AI) and digitalization solutions. During the pandemic, these tools helped and continue to assist in the remote reviewing of pathological cases. Thus, preventing delays in patient care. Companies have reported increasing adoption of digital pathology solutions post-COVID-19.

Histology And Cytology Market Report Highlights:

• The cytology segment accounted for the largest revenue share in 2024 and is expected to continue the trend in the forecast period owing to the integration of computational analytical tools for advancing cytology systems
• The consumables and reagents segment dominated the histology and cytology industry, attributed to the expanding portfolios of the entities operating in the consumable market. The instruments and analysis software system segment is expected to grow at a substantial CAGR from 2025 to 2030, attributed to the steep increase in the demand for automated histology instruments
• Drug discovery & designing segment accounted for the highest revenue share in 2024 and is anticipated to grow at the fastest CAGR over the forecast period, owing to the growing importance of cytopathology in disease understanding, further aimed at rapid drug development
• North America emerged as the highest revenue-generating region in 2024, owing to the prevalence of cancer, the presence of key players, and the developed healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type of Examination
  • 1.2.2. Product
  • 1.2.3. Application
  • 1.2.4. Regional scope
  • 1.2.5. Estimates and forecasts timeline
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased database
  • 1.4.2. GVR's internal database
  • 1.4.3. Secondary sources
  • 1.4.4. Primary research
  • 1.4.5. Details of primary research
    • 1.4.5.1. Data for primary interviews in North America
    • 1.4.5.2. Data for primary interviews in Europe
    • 1.4.5.3. Data for primary interviews in Asia Pacific
    • 1.4.5.4. Data for primary interviews in Latin America
    • 1.4.5.5. Data for Primary interviews in MEA
• 1.5. Information or Data Analysis
  • 1.5.1. Data analysis models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity flow analysis (Model 1)
  • 1.7.2. Approach 1: Commodity flow approach
  • 1.7.3. Volume price analysis (Model 2)
  • 1.7.4. Approach 2: Volume price analysis
• 1.8. List of Secondary Sources
• 1.9. List of Primary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
  • 2.2.1. Type of examination outlook
  • 2.2.2. Product outlook
  • 2.2.3. Application outlook
  • 2.2.4. Regional outlook
• 2.3. Competitive Insights

Chapter 3. Histology and Cytology Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Related/ancillary market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Rising incidence of cancer
    • 3.2.1.2. Technological developments
    • 3.2.1.3. Increase in awareness programs for cervical cancer screening
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Low sensitivity of cytology tests
    • 3.2.2.2. Conditions required for specimens and problem of mislabeled specimens
• 3.3. Histology and cytology Market Analysis Tools
  • 3.3.1. Industry Analysis - Porter's
    • 3.3.1.1. Supplier power
    • 3.3.1.2. Buyer power
    • 3.3.1.3. Substitution threat
    • 3.3.1.4. Threat of new entrant
    • 3.3.1.5. Competitive rivalry
  • 3.3.2. PESTEL Analysis
    • 3.3.2.1. Political landscape
    • 3.3.2.2. Technological landscape
    • 3.3.2.3. Economic landscape
  • 3.3.3. Pricing Analysis

Chapter 4. Histology and cytology Market: Type of Examination Estimates & Trend Analysis

• 4.1. Global Histology and Cytology Market: Type Of Examination Dashboard
• 4.2. Global Histology and Cytology Market: Type of Examination Movement Analysis
• 4.3. Global Histology and Cytology Market by Type of Examination, Revenue
• 4.4. Histology
  • 4.4.1. Histology market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.2. By Technique
    • 4.4.2.1. Microscopy
      • 4.4.2.1.1. Microscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.2. Immunohistochemistry
      • 4.4.2.2.1. Immunohistochemistry market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.3. Molecular pathology
      • 4.4.2.3.1. Molecular pathology market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.2.4. Cryostat & Microtomy
      • 4.4.2.4.1. Cryostat & Microtomy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.3. Cytology
    • 4.4.3.1. Cytology market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.4. By Technique
    • 4.4.4.1. Microscopy
      • 4.4.4.1.1. Microscopy market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.2. Immunohistochemistry
      • 4.4.4.2.1. Immunohistochemistry market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.3. Molecular pathology
      • 4.4.4.3.1. Molecular pathology market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.4.4. Cryostat & Microtomy
      • 4.4.4.4.1. Cryostat & Microtomy market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.4.5. By Application
    • 4.4.5.1. Breast Cancer
      • 4.4.5.1.1. Breast Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.2. Cervical Cancer
      • 4.4.5.2.1. Cervical Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.3. Bladder Cancer
      • 4.4.5.3.1. Bladder Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.4. Lung Cancer
      • 4.4.5.4.1. Lung Cancer market estimates and forecasts 2018 to 2030 (USD Million)
    • 4.4.5.5. Other Cancers
      • 4.4.5.5.1. Other Cancer market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Histology and cytology Market: Product Estimates & Trend Analysis

• 5.1. Global Histology and Cytology Market: Product Dashboard
• 5.2. Global Histology and Cytology Market: Product Movement Analysis
• 5.3. Global Histology and Cytology Market by Product, Revenue
  • 5.3.1. Instruments and Analysis Software System
  • 5.3.2. Instruments and analysis software system market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.3.3. Consumable and Reagents
  • 5.3.4. Consumable and reagents market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Histology and cytology Market: Application Estimates & Trend Analysis

• 6.1. Global Histology and Cytology Market: Application Dashboard
• 6.2. Global Histology and Cytology Market: Application Movement Analysis
• 6.3. Global Histology and Cytology Market by Application, Revenue
• 6.4. Drug Discovery & Designing
  • 6.4.1. Drug discovery & designing market estimates and forecasts 2018 to 2030 (USD Million)
• 6.5. Clinical Diagnostics
  • 6.5.1. Clinical diagnostics market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.2. Point-of-Care (PoC)
    • 6.5.2.1. Point-of-Care (PoC) market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5.3. Non-PoC
    • 6.5.3.1. Non-PoC market estimates and forecasts 2018 to 2030 (USD Million)
• 6.6. Research
  • 6.6.1. Research market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Histology and cytology Market: Regional Estimates & Trend Analysis by Type of Examination, Product, Application and Methodology

• 7.1. Regional Dashboard
• 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.3. North America
  • 7.3.1. U.S.
    • 7.3.1.1. Key country dynamics
    • 7.3.1.2. Regulatory framework/ reimbursement structure
    • 7.3.1.3. Competitive scenario
    • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.2. Canada
    • 7.3.2.1. Key country dynamics
    • 7.3.2.2. Regulatory framework/ reimbursement structure
    • 7.3.2.3. Competitive scenario
    • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.3.3. Mexico
    • 7.3.3.1. Key country dynamics
    • 7.3.3.2. Regulatory framework/ reimbursement structure
    • 7.3.3.3. Competitive scenario
    • 7.3.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
• 7.4. Europe
  • 7.4.1. UK
    • 7.4.1.1. Key country dynamics
    • 7.4.1.2. Regulatory framework/ reimbursement structure
    • 7.4.1.3. Competitive scenario
    • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.2. Germany
    • 7.4.2.1. Key country dynamics
    • 7.4.2.2. Regulatory framework/ reimbursement structure
    • 7.4.2.3. Competitive scenario
    • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.3. France
    • 7.4.3.1. Key country dynamics
    • 7.4.3.2. Regulatory framework/ reimbursement structure
    • 7.4.3.3. Competitive scenario
    • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.4. Italy
    • 7.4.4.1. Key country dynamics
    • 7.4.4.2. Regulatory framework/ reimbursement structure
    • 7.4.4.3. Competitive scenario
    • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.5. Spain
    • 7.4.5.1. Key country dynamics
    • 7.4.5.2. Regulatory framework/ reimbursement structure
    • 7.4.5.3. Competitive scenario
    • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.6. Norway
    • 7.4.6.1. Key country dynamics
    • 7.4.6.2. Regulatory framework/ reimbursement structure
    • 7.4.6.3. Competitive scenario
    • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.7. Sweden
    • 7.4.7.1. Key country dynamics
    • 7.4.7.2. Regulatory framework/ reimbursement structure
    • 7.4.7.3. Competitive scenario
    • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4.8. Denmark
    • 7.4.8.1. Key country dynamics
    • 7.4.8.2. Regulatory framework/ reimbursement structure
    • 7.4.8.3. Competitive scenario
    • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
• 7.5. Asia Pacific
  • 7.5.1. Japan
    • 7.5.1.1. Key country dynamics
    • 7.5.1.2. Regulatory framework/ reimbursement structure
    • 7.5.1.3. Competitive scenario
    • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.2. China
    • 7.5.2.1. Key country dynamics
    • 7.5.2.2. Regulatory framework/ reimbursement structure
    • 7.5.2.3. Competitive scenario
    • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.3. India
    • 7.5.3.1. Key country dynamics
    • 7.5.3.2. Regulatory framework/ reimbursement structure
    • 7.5.3.3. Competitive scenario
    • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.4. Australia
    • 7.5.4.1. Key country dynamics
    • 7.5.4.2. Regulatory framework/ reimbursement structure
    • 7.5.4.3. Competitive scenario
    • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.5. South Korea
    • 7.5.5.1. Key country dynamics
    • 7.5.5.2. Regulatory framework/ reimbursement structure
    • 7.5.5.3. Competitive scenario
    • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5.6. Thailand
    • 7.5.6.1. Key country dynamics
    • 7.5.6.2. Regulatory framework/ reimbursement structure
    • 7.5.6.3. Competitive scenario
    • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
• 7.6. Latin America
  • 7.6.1. Brazil
    • 7.6.1.1. Key country dynamics
    • 7.6.1.2. Regulatory framework/ reimbursement structure
    • 7.6.1.3. Competitive scenario
    • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6.2. Argentina
    • 7.6.2.1. Key country dynamics
    • 7.6.2.2. Regulatory framework/ reimbursement structure
    • 7.6.2.3. Competitive scenario
    • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
• 7.7. MEA
  • 7.7.1. South Africa
    • 7.7.1.1. Key country dynamics
    • 7.7.1.2. Regulatory framework/ reimbursement structure
    • 7.7.1.3. Competitive scenario
    • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.2. Saudi Arabia
    • 7.7.2.1. Key country dynamics
    • 7.7.2.2. Regulatory framework/ reimbursement structure
    • 7.7.2.3. Competitive scenario
    • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.3. UAE
    • 7.7.3.1. Key country dynamics
    • 7.7.3.2. Regulatory framework/ reimbursement structure
    • 7.7.3.3. Competitive scenario
    • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7.4. Kuwait
    • 7.7.4.1. Key country dynamics
    • 7.7.4.2. Regulatory framework/ reimbursement structure
    • 7.7.4.3. Competitive scenario
    • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Recent Developments & Impact Analysis, By Key Market Participants
• 8.2. Company/Competition Categorization
• 8.3. Vendor Landscape
  • 8.3.1. List of key distributors and channel partners
  • 8.3.2. Key customers
  • 8.3.3. Key company market share analysis, 2024
  • 8.3.4. Hologic, Inc.
    • 8.3.4.1. Company overview
    • 8.3.4.2. Financial performance
    • 8.3.4.3. Product benchmarking
    • 8.3.4.4. Strategic initiatives
  • 8.3.5. Abbott
    • 8.3.5.1. Company overview
    • 8.3.5.2. Financial performance
    • 8.3.5.3. Product benchmarking
    • 8.3.5.4. Strategic initiatives
  • 8.3.6. Becton, Dickinson and Company
    • 8.3.6.1. Company overview
    • 8.3.6.2. Financial performance
    • 8.3.6.3. Product benchmarking
    • 8.3.6.4. Strategic initiatives
  • 8.3.7. F. Hoffmann-La Roche Ltd
    • 8.3.7.1. Company overview
    • 8.3.7.2. Financial performance
    • 8.3.7.3. Product benchmarking
    • 8.3.7.4. Strategic initiatives
  • 8.3.8. Merck KGaA
    • 8.3.8.1. Company overview
    • 8.3.8.2. Financial performance
    • 8.3.8.3. Product benchmarking
    • 8.3.8.4. Strategic initiatives
  • 8.3.9. Thermo Fisher Scientific, Inc.
    • 8.3.9.1. Company overview
    • 8.3.9.2. Financial performance
    • 8.3.9.3. Product benchmarking
    • 8.3.9.4. Strategic initiatives
  • 8.3.10. Danaher
    • 8.3.10.1. Company overview
    • 8.3.10.2. Financial performance
    • 8.3.10.3. Product benchmarking
    • 8.3.10.4. Strategic initiatives
  • 8.3.11. Sysmex Corporation
    • 8.3.11.1. Company overview
    • 8.3.11.2. Financial performance
    • 8.3.11.3. Product benchmarking
    • 8.3.11.4. Strategic initiatives
  • 8.3.12. Trivitron Healthcare
    • 8.3.12.1. Company overview
    • 8.3.12.2. Financial performance
    • 8.3.12.3. Product benchmarking
    • 8.3.12.4. Strategic initiatives
  • 8.3.13. Koninklijke Philips N.V.
    • 8.3.13.1. Company overview
    • 8.3.13.2. Financial performance
    • 8.3.13.3. Product benchmarking
    • 8.3.13.4. Strategic initiatives